Jaguar Health, Inc. (NASDAQ:JAGX) | WebDisclosure

Basculer en Français

9480	Companies
185564	Keywords
117971	Articles
99400	Press releases

Home
Companies
Jaguar Health, Inc.

PRESS RELEASE

published on 08/27/2024 at 16:00, 1 year 3 months ago

Patent Issued in Jordan Bolsters IP Protection for Jaguar Health in the Treatment of Short Bowel Syndrome (SBS)
Jaguar Health, Inc. announces issuance of new patent for crofelemer to treat rare diseases like SBS and MVID, enhancing IP protection. Independent studies supported in US, EU, and MENA regions

Crofelemer Patent Jaguar Health Rare Diseases SBS
BRIEF

published on 08/20/2024 at 16:05, 1 year 3 months ago

Key Collaborator of Jaguar Health Joint Venture Magdalena Biosciences Receives Prestigious Alzheimer's Association Award

Jaguar Health Magdalena Biosciences Alzheimer's Award Eduardo Zimmer Botanical Drugs
BRIEF

published on 08/20/2024 at 16:05, 1 year 3 months ago

Magdalena Biosciences, collaboratrice clé de la joint-venture Jaguar Health, reçoit le prestigieux prix de l'Alzheimer's Association

Santé Jaguar Eduardo Zimmer Biosciences De Magdalena Prix Alzheimer Médicaments À Base De Plantes
PRESS RELEASE

published on 08/20/2024 at 16:00, 1 year 3 months ago

Key Collaborator of Jaguar Health Joint Venture Magdalena Biosciences Receives Prestigious Alzheimer's Association Award
Jaguar Health announces Eduardo Zimmer as 2024 Blas Frangione Early Career Achievement Award recipient for work with Magdalena Biosciences on plant-based mental health medicines

Mental Health Jaguar Health Magdalena Biosciences Plant-based Medicines Eduardo Zimmer
BRIEF

published on 08/12/2024 at 16:05, 1 year 3 months ago

Jaguar Health to Host Investor Webcast on August 13th

Crofelemer Investor Webcast Cancer Therapy-related Diarrhea Phase 3 Trial Q2 Financials
BRIEF

published on 08/12/2024 at 16:05, 1 year 3 months ago

Jaguar Health organise un webcast pour les investisseurs le 13 août

Crofelemer Essai De Phase 3 Résultats Financiers Du Deuxième Trimestre Webcast Pour Les Investisseurs Diarrhée Liée Au Traitement Du Cancer
PRESS RELEASE

published on 08/12/2024 at 16:00, 1 year 3 months ago

REMINDER: Jaguar Health to Hold Investor Webcast Tuesday, August 13th at 8:30 AM Eastern to Review Q2 Earnings and Further Review Phase 3 OnTarget Trial’s Clinically Meaningful Results in Breast and Lung Cancer Patients
Jaguar Health plans crofelemer approval pathway for breast and lung cancer based on phase 3 results. Join the investor webcast on August 13, 2024, for financial & corporate updates

Crofelemer Investor Webcast FDA Approval Jaguar Health Phase 3 Results
BRIEF

published on 08/05/2024 at 16:23, 1 year 4 months ago

Jaguar Health to Explore Approval Pathway for Crofelemer in Breast and Lung Cancer

Crofelemer Jaguar Health OnTarget Trial Breast Cancer Lung Cancer
BRIEF

published on 08/05/2024 at 16:23, 1 year 4 months ago

Jaguar Health va explorer la voie d'approbation du Crofelemer dans le traitement du cancer du sein et du poumon

Crofelemer Santé Jaguar Essai OnTarget Cancer Du Sein Cancer Du Poumon
PRESS RELEASE

published on 08/05/2024 at 16:18, 1 year 4 months ago

Jaguar Health Issues Shareholder Letter: Company to Explore Approval Pathway for Crofelemer in Breast and Lung Cancer Based on Phase 3 Results - Investor Webcast August 13th Will Review Q2 Earnings and Further Review OnTarget Trial’s Clinically Meaningf
Jaguar Health, Inc. issued a letter to shareholders regarding the upcoming webcast to review second-quarter earnings and clinical data from the recent phase 3 OnTarget trial of crofelemer for breast and lung cancer patients

Crofelemer Webcast Jaguar Health Breast Cancer Lung Cancer

Accesswire

Published on 12/06/2025 at 02:00, 5 hours 17 minutes ago

Northern Dynasty Provides Update on Board Search and Audit & Risk Committee Composition
Published on 12/06/2025 at 01:15, 6 hours 2 minutes ago

Prospect Ridge Announces Closing of Flow-Through Unit Private Placement
Published on 12/06/2025 at 00:25, 6 hours 52 minutes ago

GMV Minerals Announces Non-Brokered Private Placement Pursuant to the Listed Issuer Financing Exemption
Published on 12/06/2025 at 00:00, 7 hours 17 minutes ago

Bird River Announces Closing of $0.10 Common Share Financing
Published on 12/05/2025 at 23:30, 7 hours 47 minutes ago

55 North Mining Inc. Announces Completion of Third and Final Tranche of Private Placement for a Total of $4,202,000

View all ACCESSWIRE

EQS Group

Published on 12/05/2025 at 22:15, 9 hours 1 minute ago

CPI PROPERTY GROUP - Changes in Shareholding and Board of Directors
Published on 12/05/2025 at 22:12, 9 hours 4 minutes ago

EQS-Adhoc: CPI PROPERTY GROUP - Change to Distribution Policy
Published on 12/05/2025 at 18:58, 12 hours 18 minutes ago

EQS-Adhoc: HORNBACH Holding AG & Co. KGaA: Reduced earnings in Q3 2025/26 – Guidance for adjusted EBIT at previous year’s level still valid
Published on 12/05/2025 at 18:26, 12 hours 50 minutes ago

POS-Transaction in Own Shares
Published on 12/05/2025 at 18:15, 13 hours 1 minute ago

Completion of merger to form Helvetia Baloise Holding Ltd

Les Echos

Published on 12/05/2025 at 23:00, 8 hours 17 minutes ago

ALTAREIT : INFORMATION RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL
Published on 12/05/2025 at 23:00, 8 hours 17 minutes ago

ALTAREA : INFORMATION RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL
Published on 12/05/2025 at 23:00, 8 hours 17 minutes ago

ALTAREA : DÉCLARATION MENSUELLE DES OPÉRATIONS RÉALISÉES PAR LA SOCIÉTÉ SUR SES PROPRES TITRES NOVEMBRE 2025
Published on 12/05/2025 at 23:00, 8 hours 17 minutes ago

ALTAREIT : DÉCLARATION MENSUELLE DES OPÉRATIONS RÉALISÉES PAR LA SOCIÉTÉ SUR SES PROPRES TITRES NOVEMBRE 2025
Published on 12/05/2025 at 17:18, 13 hours 59 minutes ago

La vidéo de la réunion de présentation des résultats 2024-2025 du 5 décembre 2025 est disponible

View all LES ECHOS COMFI WIRE